UOC
CLCD

UBS O'Connor’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

UBS O'Connor’s Portfolio CLCD Stock Details CLCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-44,994
Closed -$368K – 545
2016
Q2 		$368K Sell
44,994
-45,200
-50% -$304K 0.01% 355
2016
Q1 		$559K Sell
90,194
-15,000
-14% -$93.7K 0.01% 356
2015
Q4 		$880K Buy
105,194
+4,400
+4% +$23.2K 0.01% 326
2015
Q3 		$390K Sell
100,794
-5,956
-6% -$44K 0.01% 429
2015
Q2 		$950K Buy
+106,750
New +$916K 0.02% 415

Other funds holding CLCD

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

UBS O'Connor's CLCD Position: Q3 2016 in Review

UBS O'Connor sold out of CoLucid Pharmaceuticals, Inc. (CLCD) in Q3 2016, closing a stake of 44,994 shares — an estimated $368K sold.

UBS O'Connor first reported a position in CLCD in Q2 2015 and held it in 5 quarters. The position peaked at $950K in Q2 2015. 56 funds tracked by Wall St. Rank hold CLCD as of Q3 2016.

  • UBS O'Connor reported no remaining CoLucid Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • UBS O'Connor sold 44,994 CoLucid Pharmaceuticals, Inc. shares in Q3 2016, an estimated $368K.
  • UBS O'Connor first reported a position in CoLucid Pharmaceuticals, Inc. in Q2 2015 and held it in 5 quarters.
  • UBS O'Connor's CoLucid Pharmaceuticals, Inc. position peaked at $950K in Q2 2015.
  • 56 funds tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q3 2016.

Based on UBS O'Connor's 13F filing for Q3 2016, filed 14 Nov 2016.